Barcelona, Spain – 2 February 2018: Standard medical tests miss nearly two-thirds of heart attack diagnoses, reveals research presented today at CMR 2018.1
- ‘Unrecognised’ and ‘recognised’ heart attacks have the same long-term risk of death.
- Undiagnosed patients do not receive as many medications to reduce the risk of death and other adverse outcomes as patients with known heart attacks.
Unrecognised heart attacks (myocardial infarction; MI) refer to sub-clinical events that are missed in routine medical care but are picked up by electrocardiogram (ECG) or by cardiovascular magnetic resonance (CMR) imaging, which is more accurate.2
“Unrecognised MI has a poor short-term prognosis but until now the long-term outlook was unknown,” said lead author Dr Tushar Acharya, a cardiologist at the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, US. “This study investigated long-term outcomes.”
The study included 935 community dwelling participants of ICELAND MI, a substudy of the AGES-Reykjavik epidemiology study. At the start of the study, participants underwent an ECG and CMR and were categorised into one of three groups: unrecognised MI (sub-clinical events, missed on routine medical care, but picked up by CMR), recognised MI (clinical events, also picked up by CMR), and no MI (verified by CMR).
The average age of participants was 76 years and 52% were females. At the start of the study, 91 participants (10%) had recognised MI, 156 (17%) had unrecognised MI, and 688 (74%) had no MI.3
“That means 63% (156 out of 247) of the myocardial infarctions identified by CMR were missed in routine medical care,” said Dr Acharya. “Unrecognised MI may be more common than recognised MI.”
At ten years, mortality rates were similar in patients with unrecognised and recognised MI (49% and 51%, respectively) and significantly higher than in those with no MI (30%) (p<0.001). This compares to rates at five years, where the mortality rate of patients with unrecognised MI (13%) was higher than in those with no MI (8%) but was lower than in those with recognised MI (19%).
Dr Acharya said: “This shows that with time, the mortality rate of patients with sub-clinical MI increases and is the same as those with diagnosed MI.”
Dr Acharya said: “Patients with unrecognised MI do not receive medications commonly prescribed to heart attack patients to reduce the risks of death or another heart attack. These include aspirin, high intensity statins, angiotensin converting enzyme (ACE) inhibitors and beta blockers. They should also be advised to control risk factors such as hypertension and diabetes, and may be candidates for revascularisation to open blocked arteries.”
“Knowing that they had a heart attack may also persuade some people to adopt a healthier lifestyle with adequate physical exercise and no smoking,” he added.
While population screening to identify MI using CMR is not likely to be cost-effective or practical, Dr Acharya said shifting a proportion of cardiac evaluation from traditional tests to CMR could diagnose more unrecognised MI.
He said: “Using CMR in patients with cardiac symptoms would likely detect many more heart attacks than traditional diagnostic tests. There are good therapies to treat survivors of MI so finding them early should improve prognosis.”